Insmed Inc. Stock
Price
Target price
€65.50
€65.50
0.770%
0.5
0.770%
€77.15
18.09.24 / Stuttgart Stock Exchange
WKN: A1JJA3 / Symbol: INSM / Name: Insmed / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Insmed Inc. Stock
Insmed Inc. gained 0.770% compared to yesterday.
The stock is an absolute favorite of our community with 46 Buy predictions and no Sell predictions.
With a target price of 77 € there is a slightly positive potential of 17.56% for Insmed Inc. compared to the current price of 65.5 €.
So far the community has only identified positive things for Insmed Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Insmed Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Insmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insmed Inc. | 0.770% | -0.758% | -5.072% | 164.113% | 129.021% | 187.281% | 279.270% |
| Evolus Inc | -3.360% | 5.109% | 20.000% | 68.421% | 59.116% | 114.925% | - |
| Ardelyx Inc. | -3.940% | -1.625% | 0.453% | 36.215% | -7.855% | 371.327% | 20.280% |
| Coherus Bioscien. | 1.850% | -20.402% | -16.557% | -77.568% | -68.750% | -93.667% | -95.188% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01
When examining the financials of Insmed (INSM), a player in the Biotechnology & Medical Research sector, it's essential to approach the numbers with a blend of cautious optimism and critical scrutiny. Insmed shows significant promise in terms of market capitalization and revenue growth potential, but several challenges lurk beneath the surface, particularly regarding profitability and high debt levels. Let’s dig deeper to uncover the various facets of Insmed’s financial health.
Pros of Insmed’s Financials
Market Capitalization: With a market capitalization of approximately $11 billion, Insmed positions itself as a notable player within its industry. A high market cap often signals investor confidence and robust business potential.
Comments
Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for INSM provided by MarketBeat
Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Show more
Ratings data for INSM provided by MarketBeat
Insmed Incorporated (NASDAQ: INSM) had its price target lowered by analysts at Truist Financial Co. from $88.00 to $85.00. They now have a "buy" rating on the stock.
Show more
Ratings data for INSM provided by MarketBeat